NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS) on behalf of PetMed stockholders. Our investigation concerns whether PetMed has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On June 10, 2025, PetMed issued a press release "announc[ing] it is d ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bausch + Lomb Corporation (“Bausch & Lomb” or the “Company”) (NYSE:BLCO) on behalf of Bausch & Lomb stockholders. Our investigation concerns whether Bausch & Lomb has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On March 27, 2025, Bausch & Lomb announced a v ...

Core Viewpoint - Ichor Holdings, Ltd. is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing financial results in Q1 2025, which led to a significant drop in stock price [1][2]. Financial Performance - On May 5, 2025, Ichor reported its Q1 2025 financial results, missing both EPS and revenue consensus estimates [2]. - The company reported a gross margin of 12.4%, which is below the forecasted midpoint of 14.5% [2]. - Ichor attributed the margin shortfall to purchasing more external supply than anticipated, which did not translate into expected margin flow [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Ichor on behalf of stockholders who may have suffered losses [1][3]. - The investigation focuses on whether Ichor has engaged in unlawful business practices or violated federal securities laws [1].

Group 1 - Iovance Biotherapeutics reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million compared to $73.7 million in the previous quarter [2] - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [2] - The revenue guidance revision was attributed to recent launch dynamics of the T cell immunotherapy, Amtagvi® (lifileucel), which was launched in the U.S. in the first half of 2024 [2] Group 2 - Following the announcement of the financial results and guidance revision, Iovance's stock experienced a drop on unusually heavy trading volume [2] - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance on behalf of stockholders regarding possible violations of federal securities laws and unlawful business practices [1]

Core Viewpoint - Backblaze, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following a negative report from Morpheus Research that highlighted financial missteps and questionable accounting practices [1][2]. Group 1: Investigation and Legal Actions - Bragar Eagel & Squire, P.C. is investigating potential claims against Backblaze on behalf of its stockholders [1]. - The investigation is focused on whether Backblaze has engaged in unlawful business practices and violated federal securities laws [1]. - Stockholders who have suffered losses or have information regarding these claims are encouraged to contact the law firm [3]. Group 2: Financial Performance and Market Reaction - Backblaze's stock experienced a significant decline following the release of a critical report from Morpheus Research, which detailed alleged financial missteps since the company's IPO in November 2021 [2]. - The report accused Backblaze of questionable accounting practices, including financial manipulations and inflated forecasts [2]. - The stock price dropped during intraday trading on April 24, 2025, in response to the report [2].